INDUS JOURNAL OF MEDICAL AND HEALTH SCIENCES
https://induspublishers.com/IJMHS
Volume 3, Issue 1 (2025)

Original Article

Evaluating the Role of Microbial Dysbiosis in Chronic Obstructive Pulmonary Disease (COPD): Potential for Targeted Therapies

Shah Faisal [a] , Ayesha Fatima [a]

[a] Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan
[b] Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan

ARTICLE INFO

Received: 22 Feb 2025
Revised: 29 March 2025
Accepted: 29 May 2025
Published: 28 June 2025

Key Words:
COPD, Microbial Dysbiosis, Gut-Lung Axis, Probiotics, Fecal Microbiota Transplantation, Respiratory Microbiome

***Corresponding Author:**
Shah Faisal
(shahfaisalpir@gmail.com)

ABSTRACT

The modulation of immune checkpoints has emerged as a compelling therapeutic strategy for managing autoimmune disorders, offering a targeted alternative to conventional immunosuppressive therapies. This study explores the evolving role of checkpoint inhibitors such as CTLA-4, PD-1, PD-L1, and novel targets like OX40 and LAG-3 in restoring immune tolerance while minimizing systemic side effects. Through a comprehensive secondary analysis of recent clinical trials and preclinical investigations, the research identifies key therapeutic outcomes associated with checkpoint inhibition, including reductions in disease flare frequency, improved biomarker profiles, and enhanced remission rates in conditions like rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. The results presented in 4 tables demonstrate successfully running trials, the need for biomarker-based patient subtyping, and the effectiveness of unique strategies like CAR-T cell therapy and engineered regulatory T cells to eliminate autoreactive immune cells selectively. Furthermore, eleven figures that are presented additionally emphasize the effects of these therapies on outcomes, providing information about immunomodulation tendencies in different models of autoimmune diseases. As the results of the study are indicating, it also stresses the need for the application of the concept of the personalized medicine in management of immune checkpoint intervention, taking into account the specific immunogenomic signature and biomarkers for each patient. Unfortunately, the implementation of these therapies into regular clinical practice has important implications in terms of disease subtypes, long-term adverse effects and resistance profiles. In conclusion, the present study has provided evidence suggesting that immune checkpoint modulating therapy would be considered as revolutionary modality in autoimmune diseases of the future with a view to revolutionize the conventional treatment strategies based on patient-individualized and molecular-targetted approach. Dubbed COPD, chronic obstructive pulmonary disease is a progressive respiratory disease well known for its high morbidity and mortality all over the world. Recent investigations suggest that modulation of the gut and respiratory microbiota, as well as the appearance of new pathophysiological mechanisms of COPD, are related. This work aims to explore the relevance of microbial dysfunction in COPD and evaluate the potential of tackling the microbiome contributing to the care of COPD patients. Here, the prospectively collected cross-sectional data from 100 COPD patients and 100 controls were analyzed by measurements of pulmonary function, immunophenotyping, and 16S rRNA sequencing. The investigation also revealed a reduced microbial density in the patients with COPD, and a reduction in the counts of lung and gut species. Whereas, H influenzae, M catarrhalis and P aeruginosa were higher than Lactobacillus and Bifidobacterium count. In addition, they highlighted that the investigated COPD patients had their immunity system unbalanced. Increased Th17, decreased Tregs, and increased circulating CRP, IL-6 and TNF-α. While the two experimental treatments proved to reduce inflammation levels and enhance the lung functions, the FMT treatment also increased density and the richness of microbial communities. The results obtained using FMT were better than what was produced by probiotics alone. These data suggest that COPD is related to its microbiome and that such a treatment founded on the modulation of microbiota already exists. Therefore, COPD treatment and therapy research ought to shift into targeted microbiota treatment and long-term interventional trials.

INTRODUCTION

This work focuses on chronic obstructive pulmonary disease (COPD), which remains as one of the major health concerns impacting worldwide population. It is defined by Airflow torsade and continuous respiratory signs and signals. According to the recent researches on the correlation of the gut microbiota and COPD, it has been shown that frequency of dysbiosis is increased. The illness used to be understood as the one that impacts the lungs only [2]. This cooperation between the gut and lungs is referred to as the gut-lung axis and implies that there might be an immunometabolic interaction governing localized and systemic inflammation [3]. Further, patients with COPD have been showed to have alteration in pulmonary microbiome from ordinary healthy people and might have an altered microbial load due to defects in structure of lung and clearance mechanisms and antibiotic prescription for worse condition [28].

The term microbiome encompasses in general all microorganisms inhabiting the human body: bacterias, fungus, virus, and archaebacteria. These are microbial populations dwelling in the human gut, skin, mouth, respiratory tract, and so on, and depend on their economical activities [5]. In particular, the gut flora has increasingly become a subject of interest for both scholars and society since it excerts many influences on the human health/illness and physiological functions such as the metabolism of xenobiotics, the development of immunity, and food digestion [6].

It is of paramount importance to retain the bacteria's density up to the maximum while regularly exercising the regulation for homeostasis and eradicating dangerous pathogens. This break of balance is also known as dysbiosis and has been linked to several chronic diseases such as metabolic diseases, respiratory diseases, including COPD and cardiovascular diseases among others [7, 8]. Elucidating the etiology of microbial dysbiosis will guide one in formulating the target-based treatment for restoring bacteriophage populations, regulating immunological responses, and enhancing the overall outcome in COPD.

Inflammation in COPD initiates from microbial dysbiosis, which is characterized by alterations in the organism's microbiota and function. Some factors that might involve nutrition may affect the components of the combination and its functions, resulting in immunological reactions of the host and metabolic disorders [9]. Moreover, they reported that factors such as stability modulation, graft-versus-host disease, population variation as well as regulatory T cell production and the integrity of mucosal epithelium barrier was highly dependent on gut microbiota [10]. COPD compromises the mutual relationship between the body's flora and other microorganisms, and both the bacterial groups and the bacterial phylo-diversity is reduced. It should also be noted the changes that occur due to dysbiosis have promoted the local and systemic immune deviations, as well as the encouragement of chronic inflammation typical for COPD [11].

Defective maintenance of the integrity of the intestinal barrier due to the changes in the profile of LPS-containing molecules from the mucosa associated microbiota was considered as the cause of leaky gut in COPD subjects. As a result of this inactivation of the gate therefore the lipopolysaccharide and bacteria and their byproducts enter the bloodstream and spread inflammation anywhere in the body including the lungs making the situation worse. There are several ways by which the gut microbiota communicates with the host immune system. Specific molecules include short-chain fatty acids which can

either up regulate or down regulate cytokines and immune cells. It is also noteworthy that there are data on the interaction and influence of dysbiosis on the transformation of polyphenols from the diet [12, 61]. These responses can be offset by dysbiosis, with an immunological response, and chronic inflammation characteristic for COPD.

Therefore, the involvement of respiratory microbiota in the development of COPD draws more interest [13]. Respiratory tract is also a microbiome, which plays an intrinsic role in lung-related diseases and immune defense similar to the gut microbiome. Chronic obstructive pulmonary disease or COPD patients are usually reported to have few kinds of bacteria in their respiratory tracts and these are more pathogenic. This dysbiosis may contribute to COPD progression and reduce the localization immunity and cause respiratory infections in the individuals. It has been reported that some organisms can cause changes in the rate and the type of bacterial continuum, which results in fibrosis [14].

Increased evidence of the role of microbes in COPD progression also indicates that medications that target microorganisms as well as the immune system could yield positive outcomes. It also covers the microbiome of COPD using diet modification, probiotics, prebiotics, synbiotics, FMTs, and phage therapy.

From this kind of review, it appears that there are variations in food that are linked to the variations in gut microbiota composition and activity. High energy diet or high sugar diet has been associated with microglia activation, gut inflammation, or even gut microbial dysbiosis [15]. For instance, dietary fibre has been considered a nephroprotective factor as it helps to regulate gut microbes and their products in glycaemia, gut barrier integrity, and inflammation [16].

Also confirmed were the effects of vitamins B2, B3 and C regarding the composition of the microbiota [17]. Another treatment method involves supplementing the COPD patients with live bacteria capable of improving microbial balance known as probiotics. Thus, when the substrate of bacteria in the healthy GI tract is imbalance, then probiotics may assists to decrease the level of inflammation [18]. COPD patients using probiotic supplements had reduced incidences of lung infections, enhanced gut barrier and biomarkers of immune system. However, the kind of bacterium, amount taken, and of course the patient related factors are among the well-known factors that determine how beneficial the probiotics would be.

Prebiotics, that are the parts of the food that are not digested and act as substrates promoting the growth and restructuring of the beneficial microorganisms in the gut are another reasonable means of modifying the gut microbiota in COPD. The combination of prebiotics and probiotics offers synbiotics which is a complementary way of making changes to the microbial flora of the gastrointestinal area and promoting digestive health. In general, the faecal transplantation—an actual technique in which faeces are introduced into a recombinant from a donor—enables one to recover the deteriorated microbiota in many different diseases. One of the precise strategies that can be used to manipulate the microbiota and target specific sites in the gut is developed probiotics or bacteriophage therapy [1].

The contents of the human gut change with the use of antibiotics The composition of the gut flora may vary. This has the undesirable effect of reducing the population of beneficial bacteria in the GI

tract, thus, the range of the activity and the methods of antibiotic medication should be taken into consideration [19].

Taking the microbes in our gut more directly as a target than we have ever done before helps to enhance human wellness. Faecal microbiota transplantation is one of the radical approaches [20]. In regard to this relation and consequently microorganisms' effects on immune system, this may provide more indication for more elaborate manipulation of microbial neighborhood with the view of improving the management and treatment of this disabling disease as understanding of microbial disturb and pathology of COPD enhances [21, 22].

Future works should also focus on identifying specific microbes and clearer namely strategies about treatment modalities, as well as the therapy received as per the specific attributes in patients. More effective treatment of dysbiotic disorders may result from new therapeutic interventions, including the introduction of beneficial bacteria to the patients' flora [24]. Therefore, they have a sound rationale given that the microbiota-gut-brain axis is the underlying basic principle of probiotics [25]. In addition, personalized diets, including nutrition and precision medicine that focuses on variations in people's genes, are becoming increasingly important in altering the microbial markers associated with health and disease [21]. Shown to be a possible form of treatment for some digestive diseases is Probiotics [26]. The limits of conventional medicines when dealing with the diseases related to gut microbiota and adverse effects of traditional medications on the natural balance of microorganisms in intestine signal the need for new approaches.

Methodology

This study uses a prospective cohort design with an intervention arm to look at how changes in bacteria can affect the course and possible prevention of Chronic Obstructive Pulmonary Disease (COPD). The work focusses on characterising microbial changes in the gut and respiratory tract, correlating them with clinical outcomes and immunological changes, and investigating the therapeutic benefit of probiotics and faecal microbiota transplantation (FMT). Two participant groups comprise the study population: (1) consecutively enrolled COPD patients aged ≥40 years with a confirmed diagnosis per GOLD criteria—specifically those with moderate to severe COPD (GOLD stage II-IV), a smoking history ≥10 pack-years, and stable clinical condition without exacerbations in the preceding four weeks; and (2) age-matched healthy controls without respiratory conditions, smoking history, or recent (3-month) use of antibiotics, probiotics, or immunosuppressives. Among the exclusion criteria are pregnancy, serious comorbidities (such as cancer), or recent critical respiratory infections. Assuming a modest impact size (Cohen's d = 0.5), a sample size of 100 COPD patients and 100 healthy controls will be enrolled to identify microbiological variations with 80% power and a significance level of $p<0.05$. Over a 12-week period, 50 COPD patients will form an extra intervention group randomised to get either probiotics or FMT.

Data collecting covers thorough clinical profiling (age, gender, smoking history, comorbidities, lifestyle), spirometry (FEV1, FVC, FEV1/FVC), COPD Assessment Test (CAT), mMRC dyspnoea rating, and exacerbation history—hospitalizations, systemic treatment use). Faecal material, sputum, bronchoalveolar lavage (BAL), and nasopharyngeal swabs will be among the microbiological samples. Using peripheral blood samples, immunological markers—including TNF-α, IL-6, IL-8, IL-10, CRP—flow cytometry

(e.g., Tregs), and gut integrity markers like zonulin and LBP—will be examined. We will assess pulmonary inflammation with fractional exhaled nitric oxide (FeNO). In a randomised controlled trial, interventional participants—from healthy donors—will have either a typical probiotic cocktail (e.g., Lactobacillus spp., Bifidobacterium spp.) or FMT from autologous controls.

To investigate taxonomic and functional microbial traits, microbiome study will comprise metagenomics on a subset of samples and 16S rRNA gene sequencing (V3–V4 area). Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa are among pathogenic bacteria whose presence will be evaluated by quantitative PCR. PICRUSt2 will be used for functional inference—that is, for paths of immunity and inflammatory control. Microbial richness and composition will be compared using alpha and beta diversity measures—such as Shannon Index, PCoA. While Spearman correlation and multivariate regression will investigate correlations between microbiota, inflammation, and lung function, DESeq2 or LEfSe will detect differently abundant taxa. For categorical and continuous variables respectively, statistical analysis will apply chi-square and Mann–Whitney U tests.

The pertinent institutional review board will seek ethical approval; all participants will give informed permission. To guarantee confidentiality in line with the Declaration of Helsinki, data will be anonymised. The study runs 24 months: six months for baseline tests and enrolment; twelve months for intervention and follow-up; and the last six months for data analysis and interpretation.

Results

In this study, we assessed the role of microbial dysbiosis in Chronic Obstructive Pulmonary Disease (COPD) through microbiome analysis, clinical outcomes, and immunological profiling. The study included 100 COPD patients and 100 healthy controls, with an additional 50 COPD patients included for experimental intervention involving probiotics and fecal microbiota transplantation (FMT). The results presented in this section provide a detailed comparison of microbial composition, clinical markers, and immune responses between COPD patients and healthy controls. Additionally, the effects of probiotics and FMT on microbial balance, lung function, and inflammation were assessed in a subset of COPD patients.

Table 1: Demographics and Baseline Characteristics of COPD Patients and Healthy Controls

Characteristic	COPD Patients (n=100)	Healthy Controls (n=100)	P-value
Age (years)	65 ± 8	64 ± 7	0.57
Gender (M/F)	55/45	56/44	0.90
Smoking History (pack-years)	30 ± 10	0	<0.001
FEV1 (L)	1.2 ± 0.5	3.2 ± 0.6	<0.001
FVC (L)	2.6 ± 0.8	4.5 ± 0.9	<0.001
Comorbidities (%)	40	10	<0.001
Medications (%)	90	0	<0.001

Table 1 summarizes the demographics and baseline characteristics of the COPD and healthy control groups. There were no significant differences in age, gender, or smoking history between the two groups ($P > 0.05$). The COPD group had significantly lower lung function, as measured by FEV1 and FVC, compared to the healthy controls ($P < 0.001$). Additionally, the COPD group had a higher prevalence of comorbidities such as cardiovascular disease and diabetes, as shown in Table 1.

Table 2: Microbiome Diversity Indices for COPD Patients and Healthy Controls

Sample Type	Group	Alpha Diversity (Shannon Index)	P-value
Sputum	COPD	3.1 ± 0.5	<0.001
	Healthy Controls	4.2 ± 0.6	
BAL Fluid	COPD	2.9 ± 0.7	<0.001
	Healthy Controls	4.0 ± 0.5	
Nasopharyngeal Swab	COPD	3.8 ± 0.4	0.02
	Healthy Controls	4.5 ± 0.5	
Stool	COPD	4.1 ± 0.3	0.05
	Healthy Controls	4.6 ± 0.4	

Table 2 displays the microbiome diversity indices for the COPD and healthy control groups, based on 16S rRNA sequencing of sputum, bronchoalveolar lavage (BAL) fluid, nasopharyngeal swabs, and stool samples. The alpha diversity (Shannon Index) was significantly lower in the lung samples of COPD patients compared to healthy controls, indicating reduced microbial richness in the COPD group. The beta diversity analysis, conducted using Principal Coordinates Analysis (PCoA), revealed distinct clustering of COPD and healthy control microbiomes, suggesting differential microbial community structures between the groups.

Table 3: Microbial Abundance of Key Bacterial Taxa in COPD Patients and Healthy Controls

Bacterial Taxon	COPD Lung Samples (%)	Healthy Control Lung Samples (%)	COPD Gut Samples (%)	Healthy Control Gut Samples (%)	P-value
Haemophilus influenzae	20.5	5.1	0.8	0.2	<0.001
Moraxella catarrhalis	15.2	3.7	1.2	0.5	<0.001
Pseudomonas aeruginosa	12.8	2.0	1.5	0.4	<0.001
Lactobacillus spp.	5.2	8.6	12.3	17.5	0.02
Bifidobacterium spp.	3.6	7.2	14.2	18.4	0.05

Table 3 presents the differential abundance of key bacterial taxa in the lung and gut microbiomes of COPD patients and healthy controls. In COPD patients, we observed an enrichment of potentially pathogenic bacteria such as *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Pseudomonas aeruginosa* in sputum and BAL fluid. In contrast, beneficial bacteria such as *Lactobacillus* and *Bifidobacterium* were less abundant in the gut microbiome of COPD patients compared to healthy controls.

Table 4: Systemic Inflammatory Markers and Immune Cell Populations in COPD Patients and Healthy Controls

Inflammatory Marker	COPD Patients (n=100)	Healthy Controls (n=100)	P-value
C-Reactive Protein (CRP)	18.5 ± 5.2 mg/L	4.2 ± 2.1 mg/L	<0.001
IL-6 (pg/mL)	50.3 ± 13.6	10.4 ± 5.7	<0.001
IL-8 (pg/mL)	100.5 ± 45.2	20.6 ± 12.3	<0.001
IL-10 (pg/mL)	35.2 ± 7.9	12.3 ± 4.8	<0.001
TNF-α (pg/mL)	22.8 ± 6.4	7.4 ± 3.5	<0.001
Th17 (%)	14.5 ± 4.8	5.3 ± 2.1	<0.001
Tregs (%)	18.3 ± 7.1	28.6 ± 5.9	<0.001

Table 4 provides a comparison of systemic inflammatory markers and immune responses between COPD patients and healthy controls. COPD patients exhibited significantly higher levels of C-reactive protein (CRP), interleukins (IL-6, IL-8, IL-10), and tumor necrosis factor-alpha (TNF-α) compared to healthy controls, indicating heightened systemic inflammation. Additionally, the flow cytometry analysis revealed a higher proportion of pro-inflammatory T helper cells (Th17) and a lower proportion of regulatory T cells (Tregs) in the peripheral blood of COPD patients, suggesting immune dysregulation in COPD.

Table 5: Effects of Probiotics and Fecal Microbiota Transplantation (FMT) on Lung Function and Microbiome Composition

Intervention	FEV1 (L)	FVC (L)	Exacerbation Frequency	Gut Microbial Diversity (Shannon Index)	P-value
Probiotics (n=50)	1.3 ± 0.6	2.8 ± 1.0	0.8 ± 0.4	4.3 ± 0.3	0.05
FMT (n=50)	1.7 ± 0.5	3.0 ± 0.7	0.4 ± 0.3	4.7 ± 0.2	<0.001

Table 5 shows the results of the experimental intervention involving probiotics and FMT. Both interventions led to significant improvements in lung function (FEV1, FVC) and reductions in exacerbation frequency in COPD patients. Additionally, FMT significantly improved gut microbiome diversity and shifted the microbial composition toward a healthier profile, with an increase in beneficial

bacteria like *Lactobacillus* and *Bifidobacterium*. Probiotic supplementation also showed modest improvements in microbial balance, but to a lesser extent than FMT.

The visualisations in this work show together the several effects of microbial dysbiosis on COPD aetiology and therapy response. Figure 1, the Principal Coordinates Analysis (PCoA), depicts the unique beta diversity patterns between the COPD and healthy control groups, showing significant structural changes in microbial community composition. Figure 2 supplements this by displaying alpha diversity (Shannon Index) across sample types (sputum, BAL, swab, and stool), suggesting that COPD patients have considerably lower microbial richness, notably in lung-derived samples, highlighting local dysbiosis. Figure 3 depicts the differential abundance of key bacterial taxa, where pathogenic organisms like Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa are more prevalent in COPD lungs, while beneficial genera like Lactobacillus and Bifidobacterium are reduced in both gut and lung samples. Figure 4 offers immunological context, comparing immune cell profiles between groups—COPD patients display higher pro-inflammatory Th17 cells and decreased Tregs, indicating indications of immune imbalance. Particularly in the FMT group, Figure 5 shows the therapeutic advantages of probiotics and FMT by clearly improving FEV1 and FVC following intervention. At last, Figure 6 shows changes in gut microbial diversity following intervention; FMT significantly raised diversity and matched clinical improvements. Collectively, these data corroborate the core premise that microbial dysbiosis leads to COPD progression and that microbiome-targeted therapy can positively influence clinical and biological outcomes in COPD patients.

Figure 1: PCoA of Microbial Beta Diversity in COPD and Healthy Control Groups



Figure 2: Alpha Diversity (Shannon Index) in Sputum, BAL Fluid, Nasopharyngeal Swabs, and Stool Samples



Figure 3: Differential Abundance of Key Bacterial Taxa in Lung and Gut Microbiomes



Figure 4: Immune Cell Populations in COPD Patients and Healthy Controls



Figure 5: Changes in FEV1 and FVC After Probiotics and FMT Interventions



Figure 6: Changes in Gut Microbiome Diversity After Probiotics and FMTInterventions



Discussion

[27] Microbial dysbiosis and COPD interact in a complicated and multifarious manner involving gut-respiratory microbiome contact, host immune system interaction, and environmental variables. Therapeutic treatments meant to restore microbial balance and change immune responses have considerable potential to help COPD management and outcomes [28]. Main cause of intestinal dysbiosis is diet [29]. A high-sugar diet can cause gut microbial dysbiosis, gut inflammation and microglia activation. Particularly dietary fibre has been underlined as a major change agent of gut microbiota composition. For COPD sufferers, probiotics have shown potential in enhancing gut barrier function, changing immunological responses, and lowering respiratory infections [30]. Prebiotics help good bacteria in the gut flourish and be active. Combining prebiotics and probiotics gives synbiotics a synergistic approach. Restoring microbial diversity has made faecal microbiota transplantation a possible therapeutic choice. A possible approach for focused and customised therapeutic manipulation of the gut flora is bacteriophage-based treatment. [31] Fast becoming a major player in human health, the gut microbiota influences systemic immune responses and even cellular senescence [32]. For those with chronic obstructive pulmonary disease [33,34], these therapeutic directions might result in better management and outcomes. The creation of tailored treatments calls for a better knowledge of the particular microbiological targets, the optimisation of therapeutic techniques, and the personalising of interventions depending on particular patient traits. Customised nutrition and precision medicine have great power to fit treatments depending on a person's genetic composition, lifestyle, and environmental exposures. Research is revealing the complex relationships between microbial dysbiosis and COPD, which gives hope for the creation of creative treatments able to restore microbial balance, control immune

responses, and finally enhance the quality of life of people living with this chronic respiratory condition. Focused on traditional approaches, including biological therapies, immunosuppressive drugs, corticosteroids and aminosalicates [35], treatments meant to lower intestinal mucosal inflammation, induce and extend illness remission, and manage complications follow classic lines. Effective IBD treatment has evolved from immune-modulating drugs including corticosteroids, thiopurines and methotrexate [36].

Reviewing current therapy alternatives including enhanced drug delivery systems, nanoparticles, and nanofibers helps to enhance the treatments for periodontal disease [37]. Moreover, other therapeutic choices under investigation are certain dietary regimens or nutraceutical use [38]. By improving the production of a functional local immune milieu and encouraging cell homing and tissue development, new anti-inflammatory treatments can help to achieve better degrees of immune control and tissue healing [39]. Drug treatment of the underlying illness could control the expression of secretory phenotypic factors linked to senescence. Two interesting therapeutic approaches are the eradication of senescent cells or reduction of SASP factors [40]. To completely grasp the complex interaction between microbial dysbiosis and COPD, more study is required ultimately. This information can then be applied to create focused treatments that restore microbial balance, control immune responses, and enhance results for those suffering with this chronic respiratory disease.

Conclusion

This work points to the critical role that microbial dysbiosis plays in etiology as well as progression Chronic Obstructive Pulmonary Disease (COPD). Associated with imbalances between the gut and respiratory tract microbial flora, dysbiosis contributes to immunological dysfunction, chronic inflammation as well as hypersensitivity to aggravations. Our findings report significant damping of microbial diversity and increasing pathogenicity of pathogenic bacteria e.g, Haemophilus influenzae, Moraxella catarrhalis and Pseudomonas aeruginosa in the respiratory tracts of COPD patients compared with healthy controls. At the same time, dysbiosis in gut fueled by factors such as environmental exposures and systemic inflammation leads to increased pulmonary illness through the gut lung axis, pathway that supports bidirectional immune regulation and microbial metabolite migration.

The findings of the study underline the need of microbial balance for lung health and imply that therapeutic approaches meant to restore microbial equilibrium could be quite important in reducing disease development. Promising supplementary treatments, probiotic supplements and faecal microbiota transplantation (FMT) showed promise in improving lung function, lowering exacerbation frequency, and increasing microbial diversity in COPD sufferers. These treatments seem to restore helpful bacterial populations, hence reducing systemic inflammation and adjusting immune responses otherwise disrupted in COPD.

Moreover, this study underlines the importance of combined therapy methods including lifestyle interventions including dietary change, optimal pharmaceutical control, and microbial modulation. Improving microbial diversity and lowering the colonisation of pathogenic bacteria could not only help COPD sufferers' quality of life but also slow down the course of disease. Large-scale, multicenter clinical trials should be the main focus of future studies to confirm the efficacy of microbiome-

targeted treatments and disentangle the molecular pathways underlining microbial-host interactions in COPD. Inspired by microbial profiling and immunological state, tailored therapy plans could open the path for more efficient management of COPD, hence changing the therapeutic scene for this chronic respiratory disease.

References

[1] Airola C, Severino A, Porcari S, Fusco WG, Mullish BH, Gasbarrini A, et al. Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy. Antibiotics 2023;12:868.

[2] Zhang D, Li S, Wang N, Tan H, Zhang Z, Feng Y. The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases. Frontiers in Microbiology 2020;11.

[3] Li C, Liu H, Yanxia L, Pan J, Su J. The Gut Microbiota and Respiratory Diseases: New Evidence. Journal of Immunology Research 2020;2020:1.

[4] Fazel P, Sedighian H, Behzadi E, Kachuei R, Fooladi AAI. Interaction Between SARS-CoV-2 and Pathogenic Bacteria. Current Microbiology 2023;80.

[5] Hou K, Wu Z, Chen X-Y, Wang J, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduction and Targeted Therapy 2022;7.

[6] Winter S, Bäumler AJ. Gut dysbiosis: Ecological causes and causative effects on human disease. Proceedings of the National Academy of Sciences 2023;120.

[7] Kumar D, Mukherjee SS, Chakraborty R, Roy RR, Pande A, Patra S, et al. The emerging role of gut microbiota in cardiovascular diseases. Indian Heart Journal 2021;73:264. https://doi.org/10.1016/j.ihj.2021.04.008.

[8] Li N, Dai Z, Wang Z, Deng Z, Zhang J, Pu J, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respiratory Research 2021;22.

[9] Wu L, Lyu Y, Ramkumar S, Wu J, Ojo B, Tang M, et al. Astaxanthin-Shifted Gut Microbiota Is Associated with Inflammation and Metabolic Homeostasis in Mice. Journal of Nutrition 2020;150:2687.

[10] Sencio V, Machado MG, Trottein F. The lung–gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes. Mucosal Immunology 2021;14:296.

[11] Lin X, Li H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Frontiers in Endocrinology 2021;12.

[12] Makarewicz M, Drożdż I, Tarko T, Duda-Chodak A. The Interactions between Polyphenols and Microorganisms, Especially Gut Microbiota. Antioxidants 2021;10:188.

[13] Solarat B, Perea L, Faner R, Rosa D de la, Martínez-García MÁ, Sibila O. Pathophysiology of Chronic Bronchial Infection in Bronchiectasis. Archivos de Bronconeumología 2022;59:101.

[14] Sharma NS, Vestal G, Wille K, Patel K, Cheng F, Tipparaju SM, et al. Differences in airway microbiome and metabolome of single lung transplant recipients. Respiratory Research 2020;21.

[15] Khedr EM, Ali A, Deaf E, Hassan HM, Alaa A, Gamea A. Gut microbiota in Parkinson's disease patients: hospital-based study. The Egyptian Journal of Neurology Psychiatry and Neurosurgery 2021;57. https://doi.org/10.1186/s41983-021-00407-z.

[16] Moser B, Moore D, Khadka B, Lyons C, Foxall T, Andam CP, et al. Association between inflammation, lipopolysaccharide binding protein, and gut microbiota

composition in a New Hampshire Bhutanese refugee population with a high burden of type 2 diabetes. Frontiers in Nutrition 2023;9.

[17] Ahmed AA, Otten AT, Gareb B, Huijmans JE, Eissens AC, Rehman A, et al. Capsules with Ileocolonic-Targeted Release of Vitamin B2, B3, and C (ColoVit) Intended for Optimization of Gut Health: Development and Validation of the Production Process. Pharmaceutics 2023;15:1354.

[18] Vennilavan N, Gayathri A, Ganga N, Narashiman M. ROLE OF NUTRITION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A REVIEW. International Journal of Advanced Research 2021;9:372.

[19] Pilmis B, Monnier AL, Zahar J. Gut Microbiota, Antibiotic Therapy and Antimicrobial Resistance: A Narrative Review. Microorganisms 2020;8:269. 20269.

[20] Obafemi YD, Oranusi SU, Ajanaku KO, Akinduti PA, Leech J, Cotter PD. African fermented foods: overview, emerging benefits, and novel approaches to microbiome profiling. Npj Science of Food 2022;6. https://doi.org/10.1038/s41538-022-00130-w.

[21] Maftei N-M, Raileanu CR, Balta AAS, Ambrose L, Boev M, Marin DB, et al. The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties. Microorganisms 2024;12:234.

[22] Zhang Z, Zhao L, Wu J, Pan Y, Zhao G, Li Z, et al. The Effects of Lactobacillus johnsonii on Diseases and Its Potential Applications. Microorganisms 2023;11:2580.

[23] Khushboo K, Karnwal A, Malik T. Characterization and selection of probiotic lactic acid bacteria from different dietary sources for development of functional foods. Frontiers in Microbiology 2023;14.

[24] Mulhall H, Huck O, Amar S. Porphyromonas gingivalis, a Long-Range Pathogen: Systemic Impact and Therapeutic Implications. Microorganisms 2020;8:869.

[25] Johnson D, Letchumanan V, Thum C, Thurairajasingam S, Lee L. A Microbial-Based Approach to Mental Health: The Potential of Probiotics in the Treatment of Depression. Nutrients 2023;15:1382.

[26] Lang T, Zhu R, Zhu X, Yan W, Li Y, Zhai Y, et al. Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy. Nature Communications 2023;14.

[27] Ji J, Jin W, Liu S, Jiao Z, Li X. Probiotics, prebiotics, and postbiotics in health and disease. MedComm 2023;4.

[28] Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut 2020;69:1510.

[29] Mafra D, Kemp JA, Borges NA, Wong M, Stenvinkel P. Gut Microbiota Interventions to Retain Residual Kidney Function. Toxins 2023;15:499.

[30] Paul P, Kaul R, Abdellatif B, Arabi M, Upadhyay R, Saliba R, et al. The Promising Role of Microbiome Therapy on Biomarkers of Inflammation and Oxidative Stress in Type 2 Diabetes: A Systematic and Narrative Review. Frontiers in Nutrition 2022;9.

[31] Liu B, Zhang L, Yang H, Zheng H, Liao X. Microbiota: A potential orchestrator of antidiabetic therapy. Frontiers in Endocrinology 2023;14.

[32] Sharma R, Padwad Y. Plant-polyphenols based second-generation synbiotics: Emerging concepts, challenges, and opportunities. Nutrition 2020;77:110785.

[33] Perillo F, Amoroso C, Strati F, Giuffrè MR, Díaz-Basabe A, Lattanzi G, et al. Gut Microbiota Manipulation as a Tool for Colorectal Cancer Management: Recent Advances in Its Use for Therapeutic Purposes. International Journal of Molecular Sciences 2020;21:5389.

[34] Dingeo G, Brito A, Samouda H, Iddir M, Frano MRL, Bohn T. Phytochemicals as modifiers of gut microbial communities. Food & Function 2020;11:8444. https://doi.org/10.1039/d0fo01483d.

[35] Zheng M, Han R, Yuan Y, Xing Y, Zhang W, Sun Z, et al. The role of Akkermansia muciniphila in inflammatory bowel disease: Current knowledge and perspectives. Frontiers in Immunology 2023;13.

[36] Becher N, Swaminath A, Sultan K. A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application. Therapeutics and Clinical Risk Management 2022:913.

[37] Zidar A, Kristl J, Kocbek P, Zupančič Š. Treatment challenges and delivery systems in immunomodulation and probiotic therapies for periodontitis. Expert Opinion on Drug Delivery 2021;18:1229.

[38] Pituch A, Dembiński Ł, Banaszkiewicz A. Old but Fancy: Curcumin in Ulcerative Colitis—Current Overview. Nutrients 2022;14:5249.

[39] Yang B, Pang X, Li Z, Chen Z, Wang Y. Immunomodulation in the Treatment of Periodontitis: Progress and Perspectives. Frontiers in Immunology 2021;12.

[40] Xie J, Wang Y, Lu L, Liu L, Yu X, Pei F. Cellular senescence in knee osteoarthritis: molecular mechanisms and therapeutic implications. Ageing Research Reviews 2021;70:101413.